Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Caroline Middlecote"'
Autor:
Vennie Mbaziira Nabitaka, Pamela Nawaggi, Jennifer Campbell, James Conroy, Joseph Harwell, Kinanga Magambo, Caroline Middlecote, Benvy Caldwell, Cordelia Katureebe, Norah Namuwenge, Rita Atugonza, Andrew Musoke, Joshua Musinguzi
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0232419 (2020)
Uganda adopted the integrase inhibitor dolutegravir (DTG) as part its preferred first-line HIV treatment regimen in 2018. Prior to the national rollout, the Uganda Ministry of Health and Clinton Health Access Initiative (CHAI) launched a pilot study
Externí odkaz:
https://doaj.org/article/afb7767698e04797a0cb9ec6ddc7bee2
Autor:
Jennifer Campbell, Rita Atugonza, Pamela Nawaggi, Joshua Musinguzi, James Conroy, Andrew Musoke, Caroline Middlecote, Norah Namuwenge, Kinanga A Magambo, Vennie Nabitaka, Benvy Caldwell, Cordelia Katureebe, Joseph I. Harwell
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0232419 (2020)
PLoS ONE
PLoS ONE
Uganda adopted the integrase inhibitor dolutegravir (DTG) as part its preferred first-line HIV treatment regimen in 2018. Prior to the national rollout, the Uganda Ministry of Health and Clinton Health Access Initiative (CHAI) launched a pilot study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edff0a957254153ebc43e26dda5ee804
https://doi.org/10.1371/journal.pone.0232419
https://doi.org/10.1371/journal.pone.0232419
Publikováno v:
Current opinion in HIV and AIDS. 12(4)
Purpose of review The generic antiretroviral (ARV) industry played a critical role in the massive scale-up of HIV treatment in low-income and middle-income countries since 2000. As the global community looks ahead to a universal antiretroviral regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781f5274448a19611de06f33c7145b57
https://pubmed.ncbi.nlm.nih.gov/28441147
https://pubmed.ncbi.nlm.nih.gov/28441147